A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL
Clinical trial NCT02323230 · TERMINATED
Trial details
- NCT number
- NCT02323230
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-01
- Primary completion
- 2017-06-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.